MedPath

A Phase II Study of Ro09-1978 and L-OHP in patients with resected gastric cancer

Phase 2
Conditions
Stage II, III, gastric cancer patient after curative resection
Registration Number
JPRN-jRCT2080221830
Lead Sponsor
Chugai Pharmaceutical Co., Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
100
Inclusion Criteria

Histologically confirmed stage II or III gastric cancer after D2 lymph node dissection by a standard procedure with a diagnosis of R0.

Exclusion Criteria

Lack of complete recovery from the effects of major surgery, History of treatment other than surgery for the underlying disease, Serious hypersensitivity to fluoropyrimidine or platinum compounds, etc.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Tolerability
Secondary Outcome Measures
NameTimeMethod
Efficacy, Safety
© Copyright 2025. All Rights Reserved by MedPath